AP NEWS
Press release content from BusinessWire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Advaxis to Present at LD Micro Main Event

November 28, 2018

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 28, 2018--Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will present a corporate overview at the 11 th Annual LD Micro Main Event on Tuesday, December 4, 2018 at 5:00 p.m. (Pacific). The conference will be held on December 4-6, 2018 at the Luxe Sunset Bel-Air, California.

Mr. Berlin’s presentation will be webcast live and available for replay in the Investors section of the Company’s website at www.ir.advaxis.com.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary  Lm -based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes ( Lm ) bioengineered to secrete antigen/adjuvant fusion proteins. These  Lm -based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, personalized neoantigen-directed immunotherapy, off-the-shelf, hotspot/cancer antigens neoantigen-directed immunotherapy and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181128005099/en/

CONTACT: Investors:

LHA Investor Relations

Miriam Weber Miller, 212-838-3777

mmiller@lhai.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW JERSEY

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL MEDICAL SUPPLIES

SOURCE: Advaxis, Inc.

Copyright Business Wire 2018.

PUB: 11/28/2018 08:00 AM/DISC: 11/28/2018 08:01 AM

http://www.businesswire.com/news/home/20181128005099/en

All contents © copyright 2019 The Associated Press.All rights reserved.